<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02303639</url>
  </required_header>
  <id_info>
    <org_study_id>7U/2014</org_study_id>
    <nct_id>NCT02303639</nct_id>
  </id_info>
  <brief_title>Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias</brief_title>
  <acronym>MANTRA-VT</acronym>
  <official_title>Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Ischemic Ventricular Tachyarrhythmias. A Prospective, Randomized Multicentre Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Finland Hospital District</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Finland Hospital District</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study evaluates whether catheter based radiofrequency ablation is superior to optimized
      antiarrhythmic medical therapy in preventing ventricular tachyarrhythmia relapses in patients
      with ischemic heart disease and implantable cardioverter defibrillator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is designed to evaluate whether catheter based radiofrequency ablation is superior
      to optimized antiarrhythmic medical therapy in preventing ventricular tachyarrhythmia
      relapses among patients with prior myocardial infarction and implantable cardioverter
      defibrillator (ICD). The patients have not been using using chronic antiarrhythmic
      medication. Primary end point is number of ICD therapies (defibrillations, cardioversions and
      antitachycardia pacing) and otherwise documented sustained ventricular tachycardia (duration
      more than 30 s or hemodynamically unstable ) or ventricular fibrillation episodes during 12
      months follow-up period. Secondary end points include mortality, hospitalization for cardiac
      reason, health economics, quality of life and several ICD and arrhythmia related issues.
      Total length of the follow-up is at least two years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of ventricular tachycardia (VT) or ventricular fibrillation (VF) episodes</measure>
    <time_frame>12 months</time_frame>
    <description>• Number of appropriate ICD therapies (defibrillation, cardioversion, antitachycardia pacing) for VT/VF and otherwise documented sustained VT or VF episodes at 12 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization and number of hospital days</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparative cost-effectiveness of the therapies</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life measured By SF-36 and EQ5D questionnaires</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient related outcome measured by the PHQ-9, GAD-7, ICDC-8 and EXPECT-ICD questionnaires</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of appropriate ICD therapies and sustained VT/VF episodes</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of non-sustained VT episodes</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of electrical storm episodes</measure>
    <time_frame>12 and 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first VT/VF</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reablation</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of inappropriate ICD therapies</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial fibrillation and other supraventricular arrhythmia episodes</measure>
    <time_frame>up to 24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Ventricular Tachyarrhythmia</condition>
  <arm_group>
    <arm_group_label>Radiofrequency catheter ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiofrequency catheter ablation using open-irrigated ablation catheter and 3D electroanatomical mapping</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antiarrhythmic drug therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amiodarone (or sotalol) tablet by mouth for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radiofrequency catheter ablation</intervention_name>
    <description>Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping</description>
    <arm_group_label>Radiofrequency catheter ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antiarrhythmic drug therapy</intervention_name>
    <description>Amiodarone (or sotalol) for prevention of VT/VF relapses</description>
    <arm_group_label>Antiarrhythmic drug therapy</arm_group_label>
    <other_name>amiodarone</other_name>
    <other_name>sotalol</other_name>
    <other_name>class III antiarrhyhtmic agents</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients 18-80 years of age with prior myocardial infarction and ICD (single chamber,
             dual chamber ICD or ICD with biventricular pacing capability (CRT-D)) for primary or
             secondary prevention of sudden cardiac death (SCD), who have had at least two
             documented episodes of sustained VT or VF and no chronic amiodarone treatment for
             ventricular tachyarrhythmias

        Exclusion Criteria:

          -  Age less than 18 years or more than 80 years

          -  Non-ischemic cardiomyopathy

          -  Ongoing chronic treatment of ventricular tachyarrhythmias with amiodarone,
             intolerance/contraindication to all class III antiarrhythmic drugs (i.e.,
             intolerance/contraindication to one class III agents is not excluding the patient if
             another one can be used)

          -  Contraindication to endocardial catheter ablation (e.g., intracavitary thrombi,
             contraindication to perioperative anticoagulation)

          -  Previous VT/VF ablation

          -  Open heart surgery within 3 months

          -  Prosthetic heart valve

          -  Planned revascularization (PCI or CABG)

          -  Surgery for structural heart disease or heart transplantation

          -  Pregnancy or planned pregnancy within the follow-up period

          -  Secondary cause for VT/VF (e.g., acute myocardial infarction)

          -  Patient does not want to participate

          -  Life expectancy less than 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pekka Raatikainen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Keski-Suomen sairaanhoitopiiri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pekka Raatikainen, MD, PhD</last_name>
    <phone>+358503169001</phone>
    <email>pekka.raatikainen@ksshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Central Finland Central Hospital</name>
      <address>
        <city>Jyväskylä</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart Center Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heikki Mäkynen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2014</study_first_submitted>
  <study_first_submitted_qc>November 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2014</study_first_posted>
  <last_update_submitted>August 31, 2016</last_update_submitted>
  <last_update_submitted_qc>August 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>implantable cardioverter defibrillator</keyword>
  <keyword>antiarrhythmic medication</keyword>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
    <mesh_term>Anti-Arrhythmia Agents</mesh_term>
    <mesh_term>Sotalol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

